- Home
- NCZ vs DSGN Comparison
NCZ vs DSGN Comparison
Compare NCZ & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- DSGN
- Stock Information
- Founded
- NCZ 2003
- DSGN 2017
- Country
- NCZ United States
- DSGN United States
- Employees
- NCZ N/A
- DSGN N/A
- Industry
- NCZ Finance Companies
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- DSGN Health Care
- Exchange
- NCZ Nasdaq
- DSGN Nasdaq
- Market Cap
- NCZ 228.3M
- DSGN 224.8M
- IPO Year
- NCZ N/A
- DSGN 2021
- Fundamental
- Price
- NCZ $12.36
- DSGN $3.88
- Analyst Decision
- NCZ
- DSGN Hold
- Analyst Count
- NCZ 0
- DSGN 1
- Target Price
- NCZ N/A
- DSGN $4.00
- AVG Volume (30 Days)
- NCZ 533.0K
- DSGN 92.8K
- Earning Date
- NCZ 01-01-0001
- DSGN 08-04-2025
- Dividend Yield
- NCZ 12.16%
- DSGN N/A
- EPS Growth
- NCZ N/A
- DSGN N/A
- EPS
- NCZ N/A
- DSGN N/A
- Revenue
- NCZ N/A
- DSGN N/A
- Revenue This Year
- NCZ N/A
- DSGN N/A
- Revenue Next Year
- NCZ N/A
- DSGN N/A
- P/E Ratio
- NCZ N/A
- DSGN N/A
- Revenue Growth
- NCZ N/A
- DSGN N/A
- 52 Week Low
- NCZ $2.50
- DSGN $2.60
- 52 Week High
- NCZ $3.15
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NCZ 62.67
- DSGN 49.84
- Support Level
- NCZ $12.24
- DSGN $3.81
- Resistance Level
- NCZ $12.36
- DSGN $4.15
- Average True Range (ATR)
- NCZ 0.11
- DSGN 0.29
- MACD
- NCZ -0.00
- DSGN 0.01
- Stochastic Oscillator
- NCZ 79.31
- DSGN 29.37
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.